[go: up one dir, main page]

ES2284888T3 - Administracion oral de 6-hidroxi-oximorfona utilizada como analgesico. - Google Patents

Administracion oral de 6-hidroxi-oximorfona utilizada como analgesico. Download PDF

Info

Publication number
ES2284888T3
ES2284888T3 ES02746895T ES02746895T ES2284888T3 ES 2284888 T3 ES2284888 T3 ES 2284888T3 ES 02746895 T ES02746895 T ES 02746895T ES 02746895 T ES02746895 T ES 02746895T ES 2284888 T3 ES2284888 T3 ES 2284888T3
Authority
ES
Spain
Prior art keywords
oxymorphone
hydroxy
pharmaceutical composition
use according
oral administration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES02746895T
Other languages
English (en)
Inventor
Huai-Hung Kao
Richard Smith-Carliss
Troy Mccall
David Lee
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Endo Pharmaceuticals Inc
Original Assignee
Endo Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27501826&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2284888(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Endo Pharmaceuticals Inc filed Critical Endo Pharmaceuticals Inc
Application granted granted Critical
Publication of ES2284888T3 publication Critical patent/ES2284888T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Dental Preparations (AREA)

Abstract

Utilización de 6-hidroxi oximorfona para la fabricación de una composición farmacéutica para el tratamiento del dolor, donde dicha composición farmacéutica debe suministrarse mediante administración oral.

Description

Administración oral de 6-hidroxi-oximorfona utilizada como analgésico.
\global\parskip0.900000\baselineskip
Campo de la invención
La invención hace referencia a una utilización de 6-hidroxi oximorfona para la fabricación de una composición para el tratamiento del dolor donde dicha composición farmacéutica se suministrará mediante administración oral.
Cone, Edward J; "General procedure for the isolation and identification of 6-alpha and 6-beta hydroxyl metabolites of narcotic agonists and antagonists with a hydromorphone structure", J. Chromatography, (1976), 129, 355-61 da a conocer el aislamiento y la identificación de ciertos metabolitos hidroxilos 6-alfa y 6-beta de agonistas y antagonistas narcóticos utilizando cromatografía en capa fina y cromatografía de gas. Se ha revelado que algunos de los compuestos dados a conocer presentan actividad narcótica.
La patente US-A-6.529.011 da a conocer una composición para administración nasal de metabolitos polares de analgésicos opioides que comprenden un metabolito polar de un analgésico opioide y un agente estimulador de la absorción. La morfina-6-glucuronida y la morfina-6-sulfato se revelan como metabolitos preferentes.
John L. Plummer, et al., Pain, 40 (1990) 339-347; Elsevier, "Influence of polarity on dose-response relationships of intrathecal opioids in rats"; especula que, en los humanos, los opioides mas polares que la morfina, tales como la 6-hidroxioximorfona, pueden resultar útiles en situaciones en las que se desea un alivio del dolor prolongado a continuación de una administración intratecal.
Sumario de la invención
La presente invención es tal como se describe en las reivindicaciones adjuntas. La presente invención proporciona una utilización de la 6-hidroxi oximorfona para la fabricación de una composición farmacéutica para el tratamiento del dolor donde dicha composición farmacéutica debe suministrarse mediante administración oral. Para conseguir el efecto analgésico deseado, los niveles en plasma sanguíneo de 6-hidroxi oximorfona deben elevarse hasta aproximadamente 0,2 ng/ml, más preferentemente hasta aproximadamente 0,3 ng/ml durante el tratamiento. También se proporciona una utilización de la 6-hidroxi oximorfona para la fabricación de composiciones farmacéuticas que comprenden uno o más portadores, diluyentes y excipientes para el tratamiento del dolor, donde dicha composición farmacéutica debe suministrarse mediante administración oral.
Breve descripción de las figuras
La Figura 1 es un perfil farmacocinético de la 6-hidroxi oximorfona con puntuaciones PID.
La Figura de referencia 2 es un perfil farmacocinético de la oximorfona con puntuaciones PID.
La Figura 3 es un perfil farmacocinético de la 6-hidroxi oximorfona con puntuaciones de dolor categórico.
La Figura de referencia 4 es un perfil farmacocinético de la oximorfona con puntuaciones de dolor categórico.
Las utilizaciones descritas en la presente memoria prevén la administración de una composición farmacéutica que contiene 6-hidroxi oximorfona como un ingrediente activo. En una forma de realización preferente la composición preferente comprende sólo 6-hidroxi oximorfona (excepto, por supuesto, los portadores, los diluyentes y otros excipientes). En otras formas de realización preferentes, la 6-hidroxi oximorfona puede combinarse con otros opioides u otros agentes farmacéuticos. Por ejemplo, otra forma de realización proporciona composiciones que comprenden 6-hidroxi oximorfona y su original, la oximorfona.
En dos estudios separados, se registraron los niveles en plasma sanguíneo y las indicaciones de alivio de dolor sobre un periodo posterior de 12 horas. Las Figuras 1-4 muestran una representación gráfica de los datos que combinan ambos estudios de manera que resulta posible evaluar el efecto de los niveles en plasma sanguíneo de la oximorfona y su metabolito 6-hidroxi oximorfona sobre el dolor.
La administración de oximorfona produce los niveles en plasma sanguíneo de oximorfona y de todos sus metabolitos, 6-hidroxi oximorfona. Los niveles de oximorfona alcanzan un máximo en el intervalo de 2 horas, caen ligeramente y se mantienen en un valor meseta. De manera interesante, el nivel se incrementa de nuevo a las 4-6 horas de la administración. Después de este tiempo, los niveles de oximorfona caen nuevamente y eventualmente caen a niveles cercanos a la meseta anterior.
Como con la oximorfona, los niveles en plasma sanguíneo de la 6-hidroxi oximorfona alcanzan un pico en las 2 horas después de la administración. Sin embargo, después del pico inicial, se observa una reducción más o menos constante en los niveles en plasma de la 6-hidroxi oximorfona.
Comparando estos niveles con los perfiles de dolor, resulta posible observar una correlación entre los niveles de 6-hidroxi oximorfona y el alivio del dolor. Los niveles de dolor prácticamente reflejan exactamente los niveles de 6-hidroxi oximorfona, con aumentos considerables en el alivio del dolor cerca de los picos asociados con los niveles sanguíneos de 6-hidroxi oximorfona. Por lo tanto, el alivio del dolor puede conseguirse mediante la administración exclusiva de 6-hidroxi oximorfona.
Además de los estudios farmacocinéticos, se han realizado estudios de fijación a receptores para comparar la afinidad de fijación de la 6-hidroxi oximorfona con la de la oximorfona. Los resultados se muestran en la Tabla 1. Estos resultados indican claramente que la 6-hidroxi oximorfona presenta una gran afinidad por los sitios receptores \delta, \kappa y \mu, comparable a la afinidad de fijación de su original. Los presentes inventores creen que en virtud de esta afinidad de fijación, la 6-hidroxi oximorfona presenta efectos analgésicos similares a su original, la oximorfona.
TABLA 1 Informe de ensayo
1
Por lo tanto, se han desarrollado directamente utilizaciones de la 6-hidroxi oximorfona. Se cree que el isómero \beta presenta una mayor eficacia en el tratamiento del dolor.
Las composiciones farmacéuticas que contienen 6-\alpha-hidroxi oximorfona, 6-\beta-hidroxi oximorfona o mezclas de las mismas pueden ser utilizadas en la invención.
La formulación puede ser utilizada como una suspensión, un jarabe u otro líquido, una tableta, una cápsula, una cápsula de gelatina rellena de líquido y otro medio sólido o semisólido. De manera alternativa, la composición puede presentar la forma de una formulación de liberación temporizada, incluyendo las formulaciones de liberación controlada, suspendida o prolongada. Independientemente de la formulación, se proporcionará al paciente una cantidad de 6-hidroxi oximorfona para inducir analgesia. Los niveles en plasma sanguíneo de 6-hidroxi oximorfona deben incrementarse a niveles suficientes para inducir el nivel deseado de analgesia.
La cantidad administrada dependerá de los criterios normales tales como el peso del paciente, la intensidad del dolor y otros factores. En base a los estudios farmacocinéticos, unos niveles en plasma sanguíneo de por lo menos 0,2 ng/ml proporcionarán cierta analgesia. El límite superior del nivel de plasma será establecido en última instancia por razones de seguridad. La sobredosis de cualquier opioide, incluyendo 6-hidroxi oximorfona, puede conllevar un fallo respiratorio y otros efectos secundarios no deseados y puede incluso derivar en la muerte. El nivel en plasma sanguíneo de 6-hidroxi oximorfona debe incrementarse hasta por lo menos 0,3 ng/ml. Pueden requerirse dosis subsecuentes para mantener estos niveles sanguíneos.
La administración preferente es de 6-hidroxi oximorfona con portadores y excipientes adecuados, como resultará evidente para los expertos en la materia. Por lo tanto, el plasma sanguíneo resultante en estas administraciones preferentes se encontrará considerablemente libre de oximorfona.
\global\parskip1.000000\baselineskip

Claims (6)

1. Utilización de 6-hidroxi oximorfona para la fabricación de una composición farmacéutica para el tratamiento del dolor, donde dicha composición farmacéutica debe suministrarse mediante administración oral.
2. Utilización según la reivindicación 1 en la que dicha composición farmacéutica es una forma de administración oral seleccionada de entre el grupo formado por una formulación líquida, un jarabe, una suspensión, una formulación sólida, una tableta, una cápsula, una cápsula de gelatina rellena de líquido y una formulación semisólida.
3. Utilización según cualquiera de las reivindicaciones anteriores en la que dicha composición farmacéutica comprende, además de dicha 6-hidroxi oximorfona, uno o más portadores, diluyentes y excipientes.
4. Utilización según cualquiera de las reivindicaciones anteriores en la que dicha composición farmacéutica comprende, además de dicha 6-hidroxi oximorforna, otro agente farmacéutico.
5. Utilización según la reivindicación 4 en la que dicho agente farmacéutico es un opioide.
6. Utilización según la reivindicación 5 en la que dicha composición farmacéutica comprende 6-hidroxi oximorfona y oximorfona.
ES02746895T 2001-07-06 2002-07-03 Administracion oral de 6-hidroxi-oximorfona utilizada como analgesico. Expired - Lifetime ES2284888T3 (es)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US30335701P 2001-07-06 2001-07-06
US303357P 2001-07-06
US32944401P 2001-10-15 2001-10-15
US32943201P 2001-10-15 2001-10-15
US32944501P 2001-10-15 2001-10-15
US329445P 2001-10-15
US329444P 2001-10-15
US329432P 2001-10-15

Publications (1)

Publication Number Publication Date
ES2284888T3 true ES2284888T3 (es) 2007-11-16

Family

ID=27501826

Family Applications (1)

Application Number Title Priority Date Filing Date
ES02746895T Expired - Lifetime ES2284888T3 (es) 2001-07-06 2002-07-03 Administracion oral de 6-hidroxi-oximorfona utilizada como analgesico.

Country Status (13)

Country Link
US (13) US9820982B2 (es)
EP (4) EP1414458B1 (es)
JP (4) JP4440635B2 (es)
KR (1) KR20030034171A (es)
CN (3) CN1268338C (es)
AT (1) ATE359077T1 (es)
AU (3) AU2002316582B2 (es)
BR (1) BR0205721A (es)
CA (3) CA2452871C (es)
DE (1) DE60219478T2 (es)
ES (1) ES2284888T3 (es)
NO (1) NO20031018L (es)
WO (3) WO2003004032A1 (es)

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5478577A (en) * 1993-11-23 1995-12-26 Euroceltique, S.A. Method of treating pain by administering 24 hour oral opioid formulations exhibiting rapid rate of initial rise of plasma drug level
US5965161A (en) 1994-11-04 1999-10-12 Euro-Celtique, S.A. Extruded multi-particulates
UA81224C2 (uk) 2001-05-02 2007-12-25 Euro Celtic S A Дозована форма оксикодону та її застосування
US20110104214A1 (en) 2004-04-15 2011-05-05 Purdue Pharma L.P. Once-a-day oxycodone formulations
WO2003004033A1 (en) * 2001-07-06 2003-01-16 Penwest Pharmaceuticals Company Sustained release formulations of oxymorphone
US8329216B2 (en) 2001-07-06 2012-12-11 Endo Pharmaceuticals Inc. Oxymorphone controlled release formulations
AU2002316582B2 (en) 2001-07-06 2007-03-15 Endo Pharmaceuticals, Inc. Oral administration of 6-hydroxy-oxymorphone for use as an analgesic
CA2459976A1 (en) * 2001-09-26 2003-04-03 Penwest Pharmaceuticals Company Opioid formulations having reduced potential for abuse
US7776314B2 (en) 2002-06-17 2010-08-17 Grunenthal Gmbh Abuse-proofed dosage system
AU2003270778B2 (en) 2002-09-20 2009-10-08 Alpharma Pharmaceuticals, Llc Sequestering subunit and related compositions and methods
DE10361596A1 (de) 2003-12-24 2005-09-29 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
DE10336400A1 (de) 2003-08-06 2005-03-24 Grünenthal GmbH Gegen Missbrauch gesicherte Darreichungsform
US20070048228A1 (en) 2003-08-06 2007-03-01 Elisabeth Arkenau-Maric Abuse-proofed dosage form
DE102005005446A1 (de) 2005-02-04 2006-08-10 Grünenthal GmbH Bruchfeste Darreichungsformen mit retardierter Freisetzung
CA2557439A1 (en) * 2004-03-22 2005-10-06 E.I. Dupont De Nemours And Company Orthoester-protected polyols for low voc coatings
DE102004032049A1 (de) 2004-07-01 2006-01-19 Grünenthal GmbH Gegen Missbrauch gesicherte, orale Darreichungsform
DE102005005449A1 (de) 2005-02-04 2006-08-10 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
US8394812B2 (en) 2005-08-24 2013-03-12 Penwest Pharmaceuticals Co. Sustained release formulations of nalbuphine
US8497258B2 (en) 2005-11-12 2013-07-30 The Regents Of The University Of California Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract
US20070212414A1 (en) * 2006-03-08 2007-09-13 Penwest Pharmaceuticals Co. Ethanol-resistant sustained release formulations
US20080119501A1 (en) * 2006-04-28 2008-05-22 Hein William A Immediate release oxymorphone compositions and methods of using same
HUE032156T2 (en) 2006-06-19 2017-09-28 Alpharma Pharmaceuticals Llc Pharmaceutical preparations
WO2008045060A1 (en) * 2006-10-10 2008-04-17 Penwest Pharmaceuticals Co. Robust sustained release formulations
US20080085305A1 (en) * 2006-10-10 2008-04-10 Penwest Pharmaceuticals Co. Robust sustained release formulations of oxymorphone
US20080085303A1 (en) * 2006-10-10 2008-04-10 Penwest Pharmaceuticals Co. Robust sustained release formulations of oxymorphone and methods of use thereof
AU2006349471A1 (en) * 2006-10-10 2008-04-17 Penwest Pharmaceuticals Co. Robust sustained release formulations of oxymorphone
CN101578094A (zh) * 2006-10-10 2009-11-11 潘威斯脱药物公司 稳健的羟吗啡酮缓释制剂及其使用方法
GB0624880D0 (en) * 2006-12-14 2007-01-24 Johnson Matthey Plc Improved method for making analgesics
DE102007011485A1 (de) * 2007-03-07 2008-09-11 Grünenthal GmbH Darreichungsform mit erschwertem Missbrauch
US20080318993A1 (en) * 2007-06-21 2008-12-25 Endo Pharmaceuticals, Inc. Method of Treating Pain Utilizing Controlled Release Oxymorphone Pharmaceutical Compositions and Instruction on Dosing for Hepatic Impairment
US20080318994A1 (en) * 2007-06-21 2008-12-25 Endo Pharmaceuticals, Inc. Method of Treating Pain Utilizing Controlled Release Oxymorphone Pharmaceutical Compositions and Instruction on Dosing for Renal Impairment
US20090124650A1 (en) * 2007-06-21 2009-05-14 Endo Pharmaceuticals, Inc. Method of Treating Pain Utilizing Controlled Release Oxymorphone Pharmaceutical Compositions and Instructions on Effects of Alcohol
EP2187873B1 (en) 2007-08-13 2018-07-25 Abuse Deterrent Pharmaceutical Llc Abuse resistant drugs, method of use and method of making
US8623418B2 (en) 2007-12-17 2014-01-07 Alpharma Pharmaceuticals Llc Pharmaceutical composition
JP5774853B2 (ja) 2008-01-25 2015-09-09 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング 医薬投薬形
EP2273983B1 (en) 2008-05-09 2016-07-20 Grünenthal GmbH Process for the preparation of an intermediate powder formulation and a final solid dosage form under usage of a spray congealing step
US20120065221A1 (en) * 2009-02-26 2012-03-15 Theraquest Biosciences, Inc. Extended Release Oral Pharmaceutical Compositions of 3-Hydroxy-N-Methylmorphinan and Method of Use
WO2010144865A2 (en) 2009-06-12 2010-12-16 Meritage Pharma, Inc. Methods for treating gastrointestinal disorders
EP2997965B1 (en) 2009-07-22 2019-01-02 Grünenthal GmbH Tamper-resistant dosage form for oxidation-sensitive opioids
CA2765971C (en) * 2009-07-22 2017-08-22 Gruenenthal Gmbh Hot-melt extruded controlled release dosage form
DE102009060332B4 (de) * 2009-12-23 2017-04-06 Telefónica O2 Germany GmbH & Co. OHG Verfahren und Vorrichtung zum Bereitstellen eines Telekommunikationsdienstes
AR082862A1 (es) 2010-09-02 2013-01-16 Gruenenthal Gmbh Forma de dosificacion resistente a alteracion que comprende un polimero anionico
PE20131102A1 (es) 2010-09-02 2013-10-12 Gruenenthal Chemie Forma de dosificacion resistente a manipulacion que comprende una sal inorganica
EA201400172A1 (ru) 2011-07-29 2014-06-30 Грюненталь Гмбх Устойчивая к разрушению таблетка, которая обеспечивает немедленное высвобождение лекарственного средства
AR087359A1 (es) 2011-07-29 2014-03-19 Gruenenthal Gmbh Tableta a prueba de alteracion que proporciona liberacion inmediata del farmaco
EP2819656A1 (en) 2012-02-28 2015-01-07 Grünenthal GmbH Tamper-resistant dosage form comprising pharmacologically active compound and anionic polymer
AU2013248351B2 (en) 2012-04-18 2018-04-26 Grunenthal Gmbh Tamper resistant and dose-dumping resistant pharmaceutical dosage form
US10064945B2 (en) 2012-05-11 2018-09-04 Gruenenthal Gmbh Thermoformed, tamper-resistant pharmaceutical dosage form containing zinc
JP6031599B2 (ja) 2012-07-12 2016-11-24 マリンクロッド エルエルシー 長期放出性、濫用抑止特性薬学的組成物
US20140275149A1 (en) 2013-03-15 2014-09-18 Inspirion Delivery Technologies, Llc Abuse deterrent compositions and methods of use
AR096438A1 (es) 2013-05-29 2015-12-30 Gruenenthal Gmbh Forma de dosificación resistente al uso indebido con perfil de liberación bimodal, proceso
AU2014273227B2 (en) 2013-05-29 2019-08-15 Grunenthal Gmbh Tamper-resistant dosage form containing one or more particles
KR20160031526A (ko) 2013-07-12 2016-03-22 그뤼넨탈 게엠베하 에틸렌-비닐 아세테이트 중합체를 함유하는 템퍼 내성 투여형
WO2015015146A1 (en) 2013-08-02 2015-02-05 Johnson Matthey Public Limited Company Process for the preparation of oxymorphone
BR112016010482B1 (pt) 2013-11-26 2022-11-16 Grünenthal GmbH Preparação de uma composição farmacêutica em pó por meio de criomoagem
US9062063B1 (en) 2014-03-21 2015-06-23 Johnson Matthey Public Limited Company Forms of oxymorphone hydrochloride
AU2015261060A1 (en) 2014-05-12 2016-11-03 Grunenthal Gmbh Tamper resistant immediate release capsule formulation comprising Tapentadol
MX2016015417A (es) 2014-05-26 2017-02-22 Gruenenthal Gmbh Multiparticulas protegidas contra vertido de dosis etanolico.
US10729685B2 (en) 2014-09-15 2020-08-04 Ohemo Life Sciences Inc. Orally administrable compositions and methods of deterring abuse by intranasal administration
US9918979B2 (en) 2015-01-29 2018-03-20 Johnson Matthey Public Limited Company Process of preparing low ABUK oxymorphone hydrochloride
WO2016170097A1 (en) 2015-04-24 2016-10-27 Grünenthal GmbH Tamper-resistant dosage form with immediate release and resistance against solvent extraction
JP2018526414A (ja) 2015-09-10 2018-09-13 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング 乱用抑止性の即放性製剤を用いた経口過剰摂取に対する保護
US9943513B1 (en) 2015-10-07 2018-04-17 Banner Life Sciences Llc Opioid abuse deterrent dosage forms
US10335405B1 (en) 2016-05-04 2019-07-02 Patheon Softgels, Inc. Non-burst releasing pharmaceutical composition
US10335375B2 (en) 2017-05-30 2019-07-02 Patheon Softgels, Inc. Anti-overingestion abuse deterrent compositions
ES2862209T3 (es) * 2017-07-20 2021-10-07 Intas Pharmaceuticals Ltd Composiciones orales sólidas de liberación prolongada no pulsátil que contienen betahistina

Family Cites Families (217)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US458349A (en) * 1891-08-25 Hose-coupling
US591431A (en) * 1897-10-12 Coupling for traps and pipes
US2806033A (en) 1955-08-03 1957-09-10 Lewenstein Morphine derivative
DE1517480A1 (de) 1962-11-16 1969-05-22 Permutit Co Ltd Vorrichtung zum Regenerieren von Ionenaustauschern,insbesondere fuer die Wasserenthaertung
US3400197A (en) * 1965-01-26 1968-09-03 Robins Co Inc A H Compressible sustained release pharmaceutical tablet lipid-colloidal silica gel matrix fragment granules
US3456049A (en) * 1965-05-25 1969-07-15 Ciba Geigy Corp Gradual-release tablet
IL26896A (en) 1966-01-19 1970-11-30 Endo Lab 14 - Hydroxynormorphinins and 14 - Hydroxynormorphinones
US3558768A (en) * 1969-12-19 1971-01-26 Sterling Drug Inc Sustained release pharmaceutical compositions
US3879555A (en) * 1970-11-16 1975-04-22 Bristol Myers Co Method of treating drug addicts
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3980766A (en) * 1973-08-13 1976-09-14 West Laboratories, Inc. Orally administered drug composition for therapy in the treatment of narcotic drug addiction
US3966940A (en) * 1973-11-09 1976-06-29 Bristol-Myers Company Analgetic compositions
DE2530563C2 (de) 1975-07-09 1986-07-24 Bayer Ag, 5090 Leverkusen Analgetische Arzneimittel mit vermindertem Mißbrauchspotential
US4140755A (en) * 1976-02-13 1979-02-20 Hoffmann-La Roche Inc. Sustained release tablet formulations
JPS5936110B2 (ja) * 1976-11-01 1984-09-01 株式会社日立製作所 二重点火式点火装置
US4303691A (en) * 1977-11-09 1981-12-01 Anderson, Clayton & Co. Proteinaceous food product
NO793297L (no) 1978-10-19 1980-04-22 Mallinckrodt Inc Fremgangsmaate til fremstilling av oksymorfon
US4309405A (en) * 1979-08-09 1982-01-05 American Home Products Corporation Sustained release pharmaceutical compositions
US4248858A (en) * 1979-08-09 1981-02-03 American Home Products Corporation Sustained release pharmaceutical compositions
US4252786A (en) * 1979-11-16 1981-02-24 E. R. Squibb & Sons, Inc. Controlled release tablet
US4457933A (en) * 1980-01-24 1984-07-03 Bristol-Myers Company Prevention of analgesic abuse
US4489080A (en) * 1981-06-26 1984-12-18 The Upjohn Company Process for analgesic treatment
US4366159A (en) * 1981-09-08 1982-12-28 Michael Richard Magruder Nalbuphine-narcotic analgesic composition and method of producing analgesia
US4415547A (en) * 1982-06-14 1983-11-15 Sterling Drug Inc. Sustained-release pharmaceutical tablet and process for preparation thereof
FR2530469A1 (fr) 1982-07-22 1984-01-27 Richardson Vicks Inc Composition analgesique et anti-inflammatoire contenant de la cafeine
US4587249A (en) * 1982-07-22 1986-05-06 Analgesic Associates Analgesic and anti-inflammatory compositions comprising caffeine and methods of using same
US4777174A (en) 1982-07-22 1988-10-11 Analgesic Associates Analgesic and anti-inflammatory compositions comprising caffeine and methods of using same
US4656177A (en) * 1982-07-22 1987-04-07 Analgesic Associates Analgesic and anti-inflammatory compositions comprising caffeine and methods of using same
US4464376A (en) * 1982-07-22 1984-08-07 Richardson-Vicks, Inc. Analgesic and anti-inflammatory compositions comprising caffeine and methods of using same
US4486436A (en) 1982-07-22 1984-12-04 Analgesic Associates Analgesic and anti-inflammatory compositions comprising caffeine and methods of using same
US4522804A (en) * 1983-01-03 1985-06-11 Verex Laboratories, Inc. Constant release rate solid oral dosage formulations of propranolol
US4521401A (en) * 1983-01-03 1985-06-04 Verex Laboratories, Inc. Constant release rate solid oral dosage formulations of quinidine
US4521402A (en) * 1983-01-03 1985-06-04 Verex Laboratories, Inc. Constant release rate solid oral dosage formulations of hydrazine
US4461759A (en) * 1983-01-03 1984-07-24 Verex Laboratories, Inc. Constant release rate solid oral dosage formulations of veropamil
US4567183A (en) 1983-03-11 1986-01-28 Analgesic Associates Analgesic and anti-inflammatory compositions comprising xanthines and methods of using same
US4479956A (en) 1983-04-26 1984-10-30 Analgeic Associates Analgesic compositions comprising propiram and methods of using same
US4558051A (en) 1983-10-11 1985-12-10 Richardson-Vicks, Inc. Analgesic and anti-inflammatory compositions comprising xanthines and methods of using same
JPS60100516A (ja) * 1983-11-04 1985-06-04 Takeda Chem Ind Ltd 徐放型マイクロカプセルの製造法
GB8332556D0 (en) * 1983-12-06 1984-01-11 Reckitt & Colmann Prod Ltd Analgesic compositions
JPS6124516A (ja) * 1984-07-12 1986-02-03 Fujisawa Pharmaceut Co Ltd 持続性錠剤
US4610870A (en) * 1984-10-05 1986-09-09 E. R. Squibb & Sons, Inc. Controlled release formulation
GB8430346D0 (en) * 1984-11-30 1985-01-09 Reckitt & Colmann Prod Ltd Analgesic compositions
US4569937A (en) * 1985-02-11 1986-02-11 E. I. Du Pont De Nemours And Company Analgesic mixture of oxycodone and ibuprofen
US4599114A (en) * 1985-02-11 1986-07-08 Atkinson George K Treatment of titanium dioxide and other pigments to improve dispersibility
GB8514665D0 (en) * 1985-06-11 1985-07-10 Eroceltique Sa Oral pharmaceutical composition
GB2176999B (en) 1985-06-22 1989-07-12 Stanley Stewart Davis Sustained release medicament
GB8521350D0 (en) * 1985-08-28 1985-10-02 Euro Celtique Sa Analgesic composition
GB8601204D0 (en) * 1986-01-18 1986-02-19 Boots Co Plc Therapeutic agents
IE63321B1 (en) * 1986-02-03 1995-04-05 Elan Corp Plc Drug delivery system
IT1191674B (it) * 1986-03-07 1988-03-23 Eurand Spa Formulazioni per la preparazione di farmaci a rilascio prolungato adatte alla somministrazione per via orale
SE8601624D0 (sv) * 1986-04-11 1986-04-11 Haessle Ab New pharmaceutical preparations
US4795642A (en) * 1986-05-01 1989-01-03 Pharmacaps, Inc. Gelatin-encapsulated controlled-release composition
US4861598A (en) 1986-07-18 1989-08-29 Euroceltique, S.A. Controlled release bases for pharmaceuticals
US4859461A (en) * 1986-07-30 1989-08-22 Fisons Corporation Coatable ion exchange resins
GB8626098D0 (en) * 1986-10-31 1986-12-03 Euro Celtique Sa Controlled release hydromorphone composition
US4968508A (en) * 1987-02-27 1990-11-06 Eli Lilly And Company Sustained release matrix
GB8705083D0 (en) * 1987-03-04 1987-04-08 Euro Celtique Sa Spheroids
FR2618073B1 (fr) * 1987-07-16 1990-09-07 Pf Medicament Comprimes de type a matrice hydrophile a base de salbutamol et leur procede de preparation
US4792452A (en) * 1987-07-28 1988-12-20 E. R. Squibb & Sons, Inc. Controlled release formulation
US4994276A (en) 1988-09-19 1991-02-19 Edward Mendell Co., Inc. Directly compressible sustained release excipient
SE8703881D0 (sv) * 1987-10-08 1987-10-08 Haessle Ab New pharmaceutical preparation
GB8723896D0 (en) * 1987-10-12 1987-11-18 Aps Research Ltd Controlled-release formulation
GB8728294D0 (en) * 1987-12-03 1988-01-06 Reckitt & Colmann Prod Ltd Treatment compositions
US5096714A (en) * 1988-06-28 1992-03-17 Hauser-Kuhrts, Inc. Prolonged release drug tablet formulations
DE3822095A1 (de) 1988-06-30 1990-01-04 Klinge Co Chem Pharm Fab Neue arzneimittelformulierung sowie verfahren zu deren herstellung
GB8820353D0 (en) * 1988-08-26 1988-09-28 Staniforth J N Controlled release tablet
US5135757A (en) * 1988-09-19 1992-08-04 Edward Mendell Co., Inc. Compressible sustained release solid dosage forms
US5128143A (en) * 1988-09-19 1992-07-07 Edward Mendell Co., Inc. Sustained release excipient and tablet formulation
US5169639A (en) 1988-09-19 1992-12-08 Edward Mendell Co., Inc. Controlled release verapamil tablets
US5236714A (en) * 1988-11-01 1993-08-17 Alza Corporation Abusable substance dosage form having reduced abuse potential
US5202128A (en) * 1989-01-06 1993-04-13 F. H. Faulding & Co. Limited Sustained release pharmaceutical composition
GB8903328D0 (en) * 1989-02-14 1989-04-05 Ethical Pharma Ltd Nifedipine-containing pharmaceutical compositions and process for the preparation thereof
US5126145A (en) * 1989-04-13 1992-06-30 Upsher Smith Laboratories Inc Controlled release tablet containing water soluble medicament
US4990535A (en) * 1989-05-03 1991-02-05 Schering Corporation Pharmaceutical composition comprising loratadine, ibuprofen and pseudoephedrine
GB8926612D0 (en) 1989-11-24 1990-01-17 Erba Farmitalia Pharmaceutical compositions
US5126147A (en) * 1990-02-08 1992-06-30 Biosearch, Inc. Sustained release dosage form
JP2572673B2 (ja) 1990-07-25 1997-01-16 エスエス製薬株式会社 徐放性錠剤
SE9003903D0 (sv) * 1990-12-07 1990-12-07 Astra Ab New pharmaceutical formulations
US5431922A (en) 1991-03-05 1995-07-11 Bristol-Myers Squibb Company Method for administration of buspirone
US5286497A (en) 1991-05-20 1994-02-15 Carderm Capital L.P. Diltiazem formulation
US5215758A (en) * 1991-09-11 1993-06-01 Euroceltique, S.A. Controlled release matrix suppository for pharmaceuticals
US5226331A (en) * 1991-10-03 1993-07-13 General Electric Company Apparatus and method for measuring the particle number rate and the velocity distribution of a sprayed stream
US5169638A (en) * 1991-10-23 1992-12-08 E. R. Squibb & Sons, Inc. Buoyant controlled release powder formulation
US5266331A (en) * 1991-11-27 1993-11-30 Euroceltique, S.A. Controlled release oxycodone compositions
US5681585A (en) 1991-12-24 1997-10-28 Euro-Celtique, S.A. Stabilized controlled release substrate having a coating derived from an aqueous dispersion of hydrophobic polymer
US5958459A (en) 1991-12-24 1999-09-28 Purdue Pharma L.P. Opioid formulations having extended controlled released
US5580578A (en) * 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
US5968551A (en) * 1991-12-24 1999-10-19 Purdue Pharma L.P. Orally administrable opioid formulations having extended duration of effect
US5478577A (en) 1993-11-23 1995-12-26 Euroceltique, S.A. Method of treating pain by administering 24 hour oral opioid formulations exhibiting rapid rate of initial rise of plasma drug level
GB9202464D0 (en) * 1992-02-05 1992-03-18 Danbiosyst Uk Composition for nasal administration
WO1993017673A1 (en) 1992-03-03 1993-09-16 Top Gold Pty., Limited Sustained release analgesics
DE4227385A1 (de) * 1992-08-19 1994-02-24 Kali Chemie Pharma Gmbh Pankreatinmikropellets
US5512578A (en) 1992-09-21 1996-04-30 Albert Einstein College Of Medicine Of Yeshiva University, A Division Of Yeshiva University Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by exogenous and endogenous opiod agonists
USRE36547E (en) 1992-09-21 2000-02-01 Albert Einstein College Of Medicine Of Yeshiva University Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by exogenous and endogenous opioid agonists
US5330761A (en) * 1993-01-29 1994-07-19 Edward Mendell Co. Inc. Bioadhesive tablet for non-systemic use products
IL110014A (en) * 1993-07-01 1999-11-30 Euro Celtique Sa Solid controlled-release oral dosage forms of opioid analgesics
US5662933A (en) * 1993-09-09 1997-09-02 Edward Mendell Co., Inc. Controlled release formulation (albuterol)
US5773025A (en) 1993-09-09 1998-06-30 Edward Mendell Co., Inc. Sustained release heterodisperse hydrogel systems--amorphous drugs
US5455046A (en) 1993-09-09 1995-10-03 Edward Mendell Co., Inc. Sustained release heterodisperse hydrogel systems for insoluble drugs
US5399358A (en) * 1993-11-12 1995-03-21 Edward Mendell Co., Inc. Sustained release formulations for 24 hour release of metroprolol
KR100354702B1 (ko) 1993-11-23 2002-12-28 유로-셀티크 소시에떼 아노뉨 약학조성물의제조방법및서방형조성물
GB9401894D0 (en) * 1994-02-01 1994-03-30 Rhone Poulenc Rorer Ltd New compositions of matter
US5543434A (en) * 1994-02-25 1996-08-06 Weg; Stuart L. Nasal administration of ketamine to manage pain
US5399359A (en) * 1994-03-04 1995-03-21 Edward Mendell Co., Inc. Controlled release oxybutynin formulations
HU219818B (hu) 1994-04-25 2001-08-28 Edward Mendell Co. Inc. Elnyújtott hatóanyag-leadású hordozóanyag
US5399362A (en) * 1994-04-25 1995-03-21 Edward Mendell Co., Inc. Once-a-day metoprolol oral dosage form
US5958458A (en) * 1994-06-15 1999-09-28 Dumex-Alpharma A/S Pharmaceutical multiple unit particulate formulation in the form of coated cores
US5633000A (en) 1994-06-23 1997-05-27 Axxia Technologies Subcutaneous implant
US5914131A (en) 1994-07-07 1999-06-22 Alza Corporation Hydromorphone therapy
US5556837A (en) 1994-08-01 1996-09-17 Regeneron Pharmaceuticals Inc. Methods for treating addictive disorders
US5965161A (en) 1994-11-04 1999-10-12 Euro-Celtique, S.A. Extruded multi-particulates
GB9426407D0 (en) 1994-12-30 1995-03-01 Sandoz Ltd Improvements in or relating to organic compounds
US5948438A (en) 1995-01-09 1999-09-07 Edward Mendell Co., Inc. Pharmaceutical formulations having improved disintegration and/or absorptivity
FR2729857B1 (fr) * 1995-01-27 1997-04-04 Rhone Poulenc Chimie Compositions pharmaceutiques sous forme de comprimes a liberation prolongee a base de granules en polysaccharides de haut poids moleculaire
US5686107A (en) * 1995-01-30 1997-11-11 Fmc Corporation Chewable pharmaceutical tablets
US5612053A (en) * 1995-04-07 1997-03-18 Edward Mendell Co., Inc. Controlled release insufflation carrier for medicaments
US5567754A (en) 1995-08-23 1996-10-22 Kerr-Mcgee Corporation Pigments with improved dispersibility in thermoplastic resins
CA2230690C (en) 1995-08-30 2008-12-23 Stuart L. Weg Administration of ketamine to manage pain and to reduce drug dependency
WO1997026865A1 (en) * 1996-01-29 1997-07-31 Edward Mendell Co., Inc. Sustained release excipient
US6245351B1 (en) 1996-03-07 2001-06-12 Takeda Chemical Industries, Ltd. Controlled-release composition
JP3134187B2 (ja) 1996-03-07 2001-02-13 武田薬品工業株式会社 放出制御組成物
US6103258A (en) * 1996-04-12 2000-08-15 Simon; David Lew Salts and bases of the 17-(Cyclopropylmethyl)-4,5 alpha-epoxy-6-Methylenemorphinan-3,14 diol molecule for optimizing dopamine homeostasis during administration of opioid analgesics
CA2461157C (en) 1996-04-18 2007-08-28 Penwest Pharmaceutical Co. Sustained release heterodisperse hydrogel systems - amorphous drugs
AU3581397A (en) 1996-06-28 1998-01-21 Knoll Pharmaceutical Company Slow release pharmaceutical compositions and methods of making same
US6093420A (en) * 1996-07-08 2000-07-25 Edward Mendell Co., Inc. Sustained release matrix for high-dose insoluble drugs
US6248789B1 (en) * 1996-08-29 2001-06-19 Stuart L. Weg Administration of ketamine to manage pain and to reduce drug dependency
US5891474A (en) * 1997-01-29 1999-04-06 Poli Industria Chimica, S.P.A. Time-specific controlled release dosage formulations and method of preparing same
DE19710008A1 (de) 1997-03-12 1998-09-17 Basf Ag Feste, mindestens zweiphasige Zubereitungsformen eines Opioid-Analgeticums mit verzögerter Freisetzung
AU729529B2 (en) * 1997-06-06 2001-02-01 Depomed, Inc. Gastric-retentive oral drug dosage forms for controlled release of highly soluble drugs
ATE322892T1 (de) 1997-07-02 2006-04-15 Euro Celtique Sa Stabilisierte tramadol formulierungen mit verzögerter freisetzung
US6391336B1 (en) * 1997-09-22 2002-05-21 Royer Biomedical, Inc. Inorganic-polymer complexes for the controlled release of compounds including medicinals
US5904937A (en) 1997-10-03 1999-05-18 Fmc Corporation Taste masked pharmaceutical compositions
AU9590698A (en) 1997-10-03 1999-04-27 Governors Of The University Of Alberta, The Postsurgical treatment with dichloroacetate
US6056977A (en) 1997-10-15 2000-05-02 Edward Mendell Co., Inc. Once-a-day controlled release sulfonylurea formulation
US6193991B1 (en) * 1997-10-29 2001-02-27 Atul J. Shukla Biodegradable delivery systems of biologically active substances
US6102358A (en) * 1997-11-03 2000-08-15 Mcleary; Joseph Butler Counterpoise and mounting clamp for a musical drum
PT1041987E (pt) 1997-12-22 2006-07-31 Euro Celtique Sa Forma farmaceutica de dosagem oral, compreendendo uma combinacao de um agonista de opioide e naltrexona
NZ505192A (en) 1997-12-22 2003-05-30 Euro Celtique S A method of preventing abuse of opioid dosage forms , whereby opioid agonist and opioid antagonist are only extractable together
US6375957B1 (en) * 1997-12-22 2002-04-23 Euro-Celtique, S.A. Opioid agonist/opioid antagonist/acetaminophen combinations
US6245357B1 (en) * 1998-03-06 2001-06-12 Alza Corporation Extended release dosage form
US6143325A (en) 1998-06-05 2000-11-07 Bristol-Myers Squibb Company Nefazodone dosage form
KR20000011247A (ko) * 1998-07-23 2000-02-25 김윤 다당류를이용한대장선택성약물전달조성물및약학제제
GB9816723D0 (en) 1998-08-01 1998-09-30 Boots Co Plc Therapeutic agents
DE29818454U1 (de) 1998-10-15 1999-01-14 Euroceltique S.A., Luxemburg/Luxembourg Opioid-Analgetikum
US6806294B2 (en) * 1998-10-15 2004-10-19 Euro-Celtique S.A. Opioid analgesic
KR100812832B1 (ko) * 1998-11-02 2008-03-11 엘란 코포레이션, 피엘씨 다입자 변형 방출 조성물
US6242001B1 (en) * 1998-11-30 2001-06-05 Mcneil-Ppc, Inc. Method for producing dispersible sterol and stanol compounds
EP1005863A1 (en) 1998-12-04 2000-06-07 Synthelabo Controlled-release dosage forms comprising a short acting hypnotic or a salt thereof
FR2787715B1 (fr) 1998-12-23 2002-05-10 Synthelabo Composition pharmaceutique comprenant un compose hypnotique ou un de ses sels pharmaceutiquement acceptables
PE20001396A1 (es) * 1999-01-18 2000-12-23 Gruenenthal Chemie Formulaciones medicamentosas retardadas que contienen una combinacion de un opioide o una sal fisiologicamente tolerables del mismo, un o-agonista
US6166211A (en) * 1999-03-19 2000-12-26 Endo Pharmaceuticals, Inc. Sequential benzylic oxidations of the naloxone ring system
US20030170181A1 (en) 1999-04-06 2003-09-11 Midha Kamal K. Method for preventing abuse of methylphenidate
US6306425B1 (en) 1999-04-09 2001-10-23 Southern Research Institute Injectable naltrexone microsphere compositions and their use in reducing consumption of heroin and alcohol
IE20000271A1 (en) 1999-04-13 2001-04-04 Beecham Pharm Pte Ltd Pharmaceutical Formulations of Amoxycillin and Potassium Clavulanate
EP1064937A1 (en) 1999-06-28 2001-01-03 Sanofi-Synthelabo Timed dual release dosage forms comprising a short acting hypnotic or a salt thereof
US20030118641A1 (en) * 2000-07-27 2003-06-26 Roxane Laboratories, Inc. Abuse-resistant sustained-release opioid formulation
EP1204406A2 (en) 1999-07-29 2002-05-15 Roxane Laboratories, Inc. Opioid sustained-released formulation
KR100345214B1 (ko) 1999-08-17 2002-07-25 이강춘 생체적합성 고분자가 수식된 펩타이드의 비점막 전달
JP4913298B2 (ja) 1999-08-27 2012-04-11 ブルックウッド ファーマシューティカルズ，インコーポレイティド 注射可能なブプレノルフィン微粒子組成物及びその使用
US6436977B1 (en) 1999-09-29 2002-08-20 Pfizer Inc. Dosing regimens for lasofoxifene
CA2352211C (en) 1999-09-30 2009-03-24 Edward Mendell Co., Inc. Sustained release matrix systems for highly soluble drugs
ES2374717T3 (es) 1999-10-29 2012-02-21 Euro-Celtique S.A. Formulaciones de hidrocodona de liberación controlada.
AP2002002553A0 (en) 1999-12-23 2002-06-30 Pfizer Prod Inc Hydrogel-driven Drug Dosoge Form.
US6555127B2 (en) * 2000-01-19 2003-04-29 Pharmaceutical Discovery Corporation Multi-spike release formulation for oral drug delivery
US6716449B2 (en) * 2000-02-08 2004-04-06 Euro-Celtique S.A. Controlled-release compositions containing opioid agonist and antagonist
OA12215A (en) * 2000-02-08 2006-05-09 Euro Celtique Sa Tamper-resistant oral opioid agonist formulations.
WO2002005647A1 (en) 2000-07-13 2002-01-24 Euro-Celtique, S.A. Salts and bases of 17-(cyclopropylmethyl)-4,5 alpha-epoxy-6-methylenemorphinan-3,14 diol for optimizing dopamine homeostasis during administration of opioid analgesics
AU2001275095A1 (en) * 2000-07-17 2002-01-30 Opt-E-Scrip, Inc. Single-patient drug trials used with accumulated database
US6296842B1 (en) 2000-08-10 2001-10-02 Alkermes Controlled Therapeutics, Inc. Process for the preparation of polymer-based sustained release compositions
US6948492B2 (en) 2000-08-15 2005-09-27 University Of Kentucky Research Foundation Programmable multi-dose intranasal drug delivery device
EP1322303A1 (en) 2000-10-03 2003-07-02 Penwest Pharmaceuticals Co. Delivery system for multi-pharmaceutical active materials at various release rates
US20020187192A1 (en) 2001-04-30 2002-12-12 Yatindra Joshi Pharmaceutical composition which reduces or eliminates drug abuse potential
ES2361148T3 (es) 2001-05-11 2011-06-14 Endo Pharmaceuticals Inc. Forma de dosificación de opioides de liberación controlada resistente al abuso.
CN1592609A (zh) 2001-05-11 2005-03-09 恩德制药公司 抗滥用阿片样物质剂型
US7125561B2 (en) 2001-05-22 2006-10-24 Euro-Celtique S.A. Compartmentalized dosage form
US20030064122A1 (en) * 2001-05-23 2003-04-03 Endo Pharmaceuticals, Inc. Abuse resistant pharmaceutical composition containing capsaicin
US8329216B2 (en) * 2001-07-06 2012-12-11 Endo Pharmaceuticals Inc. Oxymorphone controlled release formulations
AU2002316582B2 (en) 2001-07-06 2007-03-15 Endo Pharmaceuticals, Inc. Oral administration of 6-hydroxy-oxymorphone for use as an analgesic
WO2003004033A1 (en) 2001-07-06 2003-01-16 Penwest Pharmaceuticals Company Sustained release formulations of oxymorphone
WO2003007802A2 (en) 2001-07-18 2003-01-30 Euro-Celtique, S.A. Pharmaceutical combinations of oxycodone and naloxone
KR20040025741A (ko) 2001-08-06 2004-03-25 유로-셀티크 소시에떼 아노뉨 오피오이드 남용을 방지하기 위한 조성물 및 방법
US7332182B2 (en) * 2001-08-06 2008-02-19 Purdue Pharma L.P. Pharmaceutical formulation containing opioid agonist, opioid antagonist and irritant
US7144587B2 (en) * 2001-08-06 2006-12-05 Euro-Celtique S.A. Pharmaceutical formulation containing opioid agonist, opioid antagonist and bittering agent
HUP0401195A3 (en) 2001-08-06 2006-11-28 Euro Celtique Sa Compositions to prevent abuse of opioids containing aversive agent and process of their preparation
US20030068375A1 (en) * 2001-08-06 2003-04-10 Curtis Wright Pharmaceutical formulation containing gelling agent
WO2003015531A2 (en) 2001-08-06 2003-02-27 Thomas Gruber Pharmaceutical formulation containing dye
US20030157168A1 (en) * 2001-08-06 2003-08-21 Christopher Breder Sequestered antagonist formulations
US7141250B2 (en) * 2001-08-06 2006-11-28 Euro-Celtique S.A. Pharmaceutical formulation containing bittering agent
SI1414451T1 (sl) 2001-08-06 2009-10-31 Euro Celtique Sa Formulacije opioidnega agonista s sproščanja sposobnim in sekvestriranim antagonistom
US7842307B2 (en) * 2001-08-06 2010-11-30 Purdue Pharma L.P. Pharmaceutical formulation containing opioid agonist, opioid antagonist and gelling agent
US20030044458A1 (en) * 2001-08-06 2003-03-06 Curtis Wright Oral dosage form comprising a therapeutic agent and an adverse-effect agent
US7157103B2 (en) * 2001-08-06 2007-01-02 Euro-Celtique S.A. Pharmaceutical formulation containing irritant
US20030049272A1 (en) * 2001-08-30 2003-03-13 Yatindra Joshi Pharmaceutical composition which produces irritation
US20030059397A1 (en) 2001-09-17 2003-03-27 Lyn Hughes Dosage forms
US20030068276A1 (en) 2001-09-17 2003-04-10 Lyn Hughes Dosage forms
CA2459976A1 (en) * 2001-09-26 2003-04-03 Penwest Pharmaceuticals Company Opioid formulations having reduced potential for abuse
US20030125347A1 (en) * 2001-11-02 2003-07-03 Elan Corporation Plc Pharmaceutical composition
US20030158264A1 (en) 2002-02-20 2003-08-21 Ramachandran Radhakrishnan Orally administrable pharmaceutical formulation comprising ephedrine hydrochloride and process for preparing the same
AU2003209933A1 (en) 2002-02-27 2003-09-09 Ab Science Use of tyrosine kinase inhibitors for treating substance use disorders
AU2003220551A1 (en) 2002-03-26 2003-10-13 Euro-Celtique S.A. Sustained-release gel coated compositions
US7524515B2 (en) * 2003-01-10 2009-04-28 Mutual Pharmaceuticals, Inc. Pharmaceutical safety dosage forms
EP1831225A2 (en) * 2004-11-19 2007-09-12 The Regents of the University of California Anti-inflammatory pyrazolopyrimidines
US20060193912A1 (en) 2005-02-28 2006-08-31 Penwest Pharmaceuticals Co. Controlled release O-desmethylvenlafaxine formulations
EP1909769A2 (en) 2005-08-01 2008-04-16 Alpharma, Inc. Alcohol resistant pharmaceutical formulations
ES2441766T3 (es) 2005-08-24 2014-02-06 Endo Pharmaceuticals Inc. Formulaciones de nalbufina de liberación sostenida
PL116330U1 (en) 2005-10-31 2007-04-02 Alza Corp Method for the reduction of alcohol provoked rapid increase in the released dose of the orally administered opioide with prolonged liberation
WO2007078895A2 (en) 2005-12-30 2007-07-12 Biovail Laboratories International S.R.L. Modified release formulations of tramadol and uses thereof
US20070212414A1 (en) 2006-03-08 2007-09-13 Penwest Pharmaceuticals Co. Ethanol-resistant sustained release formulations
US20080119501A1 (en) * 2006-04-28 2008-05-22 Hein William A Immediate release oxymorphone compositions and methods of using same
US20080085303A1 (en) * 2006-10-10 2008-04-10 Penwest Pharmaceuticals Co. Robust sustained release formulations of oxymorphone and methods of use thereof
AU2006349471A1 (en) 2006-10-10 2008-04-17 Penwest Pharmaceuticals Co. Robust sustained release formulations of oxymorphone
US20080085305A1 (en) * 2006-10-10 2008-04-10 Penwest Pharmaceuticals Co. Robust sustained release formulations of oxymorphone
WO2008045060A1 (en) 2006-10-10 2008-04-17 Penwest Pharmaceuticals Co. Robust sustained release formulations
US20080085304A1 (en) * 2006-10-10 2008-04-10 Penwest Pharmaceuticals Co. Robust sustained release formulations
CN101578094A (zh) 2006-10-10 2009-11-11 潘威斯脱药物公司 稳健的羟吗啡酮缓释制剂及其使用方法
US20080318993A1 (en) 2007-06-21 2008-12-25 Endo Pharmaceuticals, Inc. Method of Treating Pain Utilizing Controlled Release Oxymorphone Pharmaceutical Compositions and Instruction on Dosing for Hepatic Impairment
US20080318994A1 (en) 2007-06-21 2008-12-25 Endo Pharmaceuticals, Inc. Method of Treating Pain Utilizing Controlled Release Oxymorphone Pharmaceutical Compositions and Instruction on Dosing for Renal Impairment

Also Published As

Publication number Publication date
DE60219478D1 (en) 2007-05-24
EP1414458B1 (en) 2007-04-11
CA2452871A1 (en) 2003-01-16
EP2311460A1 (en) 2011-04-20
CN1538846A (zh) 2004-10-20
US20180338967A1 (en) 2018-11-29
AU2002316582B2 (en) 2007-03-15
NO20031018L (no) 2003-05-06
US20040214849A1 (en) 2004-10-28
US20030157167A1 (en) 2003-08-21
JP2005515966A (ja) 2005-06-02
JP4440635B2 (ja) 2010-03-24
WO2003004031A1 (en) 2003-01-16
US20080262013A1 (en) 2008-10-23
JP2005520778A (ja) 2005-07-14
JP2004536832A (ja) 2004-12-09
BR0205721A (pt) 2003-09-30
US20150011577A1 (en) 2015-01-08
KR20030034171A (ko) 2003-05-01
ATE359077T1 (de) 2007-05-15
US20070098793A1 (en) 2007-05-03
US20160136152A1 (en) 2016-05-19
EP1414458A1 (en) 2004-05-06
CA2452871C (en) 2011-10-04
DE60219478T2 (de) 2008-01-03
NO20031018D0 (no) 2003-03-05
CN1551770A (zh) 2004-12-01
US8309122B2 (en) 2012-11-13
CN1610551A (zh) 2005-04-27
AU2002318211B2 (en) 2007-07-12
EP1406630A1 (en) 2004-04-14
US20140134250A1 (en) 2014-05-15
US20210008063A1 (en) 2021-01-14
JP2009114209A (ja) 2009-05-28
AU2002320309B2 (en) 2007-07-12
US20030130297A1 (en) 2003-07-10
EP1404333A1 (en) 2004-04-07
US9820982B2 (en) 2017-11-21
CA2452872A1 (en) 2003-01-16
US20070098792A1 (en) 2007-05-03
US20070134328A1 (en) 2007-06-14
WO2003004032A1 (en) 2003-01-16
WO2003004030A1 (en) 2003-01-16
CN1268338C (zh) 2006-08-09
CA2452874A1 (en) 2003-01-16
US20090192183A1 (en) 2009-07-30

Similar Documents

Publication Publication Date Title
ES2284888T3 (es) Administracion oral de 6-hidroxi-oximorfona utilizada como analgesico.
AU2002316582A1 (en) Oral administration of 6-hydroxy-oxymorphone for use as an analgesic
ES2244992T3 (es) Metodo y composicion potenciada para tratar la migraña.
RU2407532C9 (ru) Комбинации, предназначенные для лечения заболеваний, включающих пролиферацию клеток
ES2427976T5 (es) Composición de sal de fentanilo para administración nasal
RU2314810C2 (ru) Способ лечения с использованием лекарственных форм, содержащих фармацевтические композиции 5,8,14-триазатетрацикло[10.3.1.0 (2,11).0(4,9)] гексадека-2( 11),3,5,7,9-пентаена
ES2930899T3 (es) Monohidrato de gaboxadol en el tratamiento del tinnitus
WO2005043971A3 (en) Methods of using and compositions comprising selective cytokine inhibitory drugs for treatment, modification and management of pain
ES2398925T3 (es) Uso de formulaciones opioides en dispositivos para administración de fármacos sin aguja
NO20065638L (no) Formuleringer med kontrollert frigivelse inneholdende vardenafil
ATE165973T1 (de) Sumatriptan enthaltende arzneimittel
KR20010022041A (ko) 뇌 신경혈관 장애 및 근육성 두통 억제용 조성물, 키트 및방법
SI1383752T1 (sl) Devterirani 3-piperidinopropiofenoni in zdravila, ki vsebujejo te spojine
WO2004037207A3 (en) Methods of using and compositions comprising selective cytokine inhibitory drugs for treatment, modification and management of pain
KR880005930A (ko) 탐닉 치료용 의약품
KR880007074A (ko) 의약품
CY1110184T1 (el) Φαρμακευτικη συνθεση για μαλακες καψουλες για χορηγηση απο το στομα η οποια περιεχει βινορελβινη και μεθοδος θεραπειας
AU2008322739C1 (en) Use of anti-bacterial compounds having an anaesthetic effect
ES2267301T3 (es) Composicion bifasica con tramadol.
RU2005135649A (ru) Комбинации пароксетина и 4-(s)-(4-ацетилпиперазин-1-ил)-2-(r)-(4-фтор-2-метилфенил)пиперидин-1-карбоновой кислоты [1-(r)-(3, 5-бис-трифторметилфенил)этил]метиламида для лечения депрессии и/или тревоги
MacGregor Anti-emetics
KR900004340A (ko) 의약제
Woroń Drug selection in the treatment of breakthrough pain: how the pharmacokinetic profile of drugsis to be translated into clinical practice
DK0942729T3 (da) Anvendelse af NK-1-receptorantagonister til behandling af stresslidelser
SE0102888D0 (sv) New formulation